Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Bevacizumab, and Olaparib in Recurrent Ovarian Cancer
NCT05158062Phase 2Unknown
- Start
- Apr 2022
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian epithelial cancer. Primary endpoint: Two-year progression-free survival rate at 2 years. Status: unknown.
02
Drugs
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT05158062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158062.